Healthy adult subjects Sample collection for evaluating analysis and sampling methods in antidoping
Conditions
Interventions
Blood and urine samples are collected from the subjects who are admitted to the hospital two days prior to the administration of control drug on the day before the administration of the drug until 216
Sponsors
LSI Medience Corporation
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Sex:Male Age:20 or more years old, less than 40 years old. Weight:50 kg or more. BMI The weight (kg) / height (m) 2 :17.6 or more and less than 26.4(at the time of a prior inspection). There is consent to clinical test participation.
Exclusion criteria
Exclusion criteria: Hypersensitivity to drugs, A history of alcohol or drug addiction, Under the medical treatment or it may treatof a certain disease, Ethical or OTC pharmaceuticals administered within two weeks before scheduled administation of the study drug, Supplement, grapefruit or its products, or foods cotaing Western St. John's comsumed within one week before scheduled administation of the study drug, and Not less than 200mL of blood is collected within 30 days or not less than 400mL of blood is collected within 90 days before scheduled administation of the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time, type, and volume of samples collected to confirm changes in blood parameters and detectable period of plasma expander, etc. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time, type, and volume of sample collected to evaluate the appropriateness of using blood for the analysis of plasma expander compared to urine samples. | — |
Countries
Japan
Contacts
Public ContactMitsuhiko Sato
LSI Medience Corporation
Outcome results
None listed